Replay available

IRIDEX (NASDAQ:IRIX) Q1 2021 Earnings Call

IRIDEX (NASDAQ:IRIX) Q1 2021 earnings call, held 2021-05-11. Watch the replay and read the transcript on 6ix.

Tue, May 11, 2021 at 5:00 PMendedReplay
IRIDEX (NASDAQ:IRIX) Q1 2021 Earnings Call
Company
IRIDEX Corporation (NASDAQ:IRIX)
Period
Q1 2021 earnings call
Date
Tue, May 11, 2021, 5:00 PM ET
Replay
Watch the replay on this page · 31 min
Results news release
Iridex Announces First Quarter 2021 Financial Results · Tue, May 11, 2021

On 6ix: 6ix.com/event/iridex-corporation-irix-q1-2021-earnings-call

Replay

Transcript

Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.

0:00 Good day and thank you for standing by. Welcome to the Q1 2021 Airdex Earnings Conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1 on your telephone. If you require any further assistance, please press star 0. I would now like to hand the conference over to your speaker today, Hunter Cobby, Investor Relations. Please go ahead.

0:36 Thank you and thank you all for participating in today's call. Joining me are Dave Bruce, Chief Executive Officer, and Vlad Amon, Interim Chief Financial Officer. Earlier today, Veridex released financial results for the quarter ended April 3rd, 2021. A copy of the presentation is available on the company's website. Before we begin, I'd like to remind you that managers will make statements during this call. that include forward-looking statements within the meaning of the Federal Securities Laws which are made pursuant to the state-powered revisions of the Private Securities Litigation Reform Act of 1995. Any statements made during this call are not statements of historical fact, including but not limited to statements concerning our strategic goals and priorities, product development matters, sales trends, and markets in which we operate.

1:22 Our forward-looking statements are based upon our current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place reliance on these statements. For a discussion of these risks and uncertainties associated with our business, please see our most recent Form 10-K, Inform 10 Key Finds with SEC. Thank you all for joining us.

2:13 Our first quarter was marked by strong top-line performance, continued operational execution, and substantial progress across our strategic initiatives. On today's call, I'll cover the highlights of our first quarter 2021 results, how we're focused today, and how we'll execute for our longer-term market opportunity. Fuad will cover our financial results and guidance for the fiscal year, and then we'll open the call for questions. SpiritX had a strong start to 2021, achieving a multi-year record for first quarter total revenue. Revenue in the first quarter was $12.0 million, a 33% year-over-year increase.

2:58 This improvement was the result of a number of factors. First, we maintained strong momentum in our glaucoma product family with record international G6 probe sales and a significant rebound in console sales. Our Retina business also rebounded strongly with sales up 61% from the prior year to $6.7 million. This included a contribution of about $1.1 million from Pascal Products acquired as part of our collaboration agreement with Topcon. Third, we believe our sales and marketing programs are having effect, building awareness and demonstrating the many benefits of our non-incisional glaucoma therapy.

3:43 In short, creating sales traction. Overall, we were very pleased to see demand for Iridex products increasing, both in our glaucoma and retina markets and in the U.S. and internationally. I'm encouraged by the multiple growth catalysts we have on the horizon including improved sales infrastructure, broader distribution capabilities, a pipeline of enhanced products, expanded key opinion leader support and industry awareness. And importantly, we have a significantly strengthened balance sheet in place to support strategic initiatives designed to leverage these catalysts.

4:33 We added $19.5 million in funds from TopCon Corporation as part of the strategic collaboration we closed in March. And combined with continued strong cash management, we ended the quarter with a cash position of $28 million. Our cash usage in the quarter was approximately $600,000 from operations and $500,000 from non-recurring payments associated with the TopCon transaction. This was despite already having begun our investments in sales and marketing programs designed to accelerate growth, which I'll explain in a minute. Turning now to focus on the glaucoma business. Our Cycle G6 product family revenue was $3.3 million, an increase of 15% year over year.

5:20 During the first quarter, we saw 13,600 Cyclo-G6 probes, a 4% year-over-year increase, despite nearing COVID-19 impacts, which you should recall were particularly widespread early in the quarter when countries such as Germany reimposed lockdowns. The sales strength was broad-based, the volumes from Japan were strong, and Asia Pacific, Europe, Middle East, Africa, and Latin America all recovered meaningfully, driving international glaucoma probe sales higher by 18% year-over-year and setting a new quarterly record for international probe volumes. In the U.S., probe sales were slightly below Q1 of 2020, which we attribute to a combination of relative strength last year as customers bought inventory pre-lockdown and this year's restrictive environment in the first half of the first quarter when U.S.

6:20 COVID cases were peaking. Overall, the growth we've seen in glaucoma probe sales is encouraging on many levels. Importantly, it signals our strategic shift to emphasize higher physician utilization is showing results while in parallel highlighting growing customer support for the enhancements in our revised probe, which was launched last year. Moving to our Cyclo-G6 glaucoma laser systems, we sold 64 units in the first quarter of 2021 compared to 38 in the prior year. This increase is a rebound from the understandable hesitancy on capital purchases last year as we entered the pandemic. We now see business opening toward more normal operation.

7:07 Turning to Retina, we saw related product revenue grow nearly 61% year-over-year, including a 16% contribution from sales of Pascal products acquired from TopCon. The surge in revenue can be attributed to a return from deferred purchases relating to COVID, but also to our renewed commitment to our retina product line. As you can see, we're enjoying a return on those investments as the business landscape improves. As we announced earlier, in the first quarter, we entered into a strategic collaboration with Topcon Corporation's $430 million revenue eye care division. As part of this collaboration, Topcon purchased exclusive distribution rights in Asia Pacific and key EMEA markets for Iridex Retina and Glaucoma products, which accounted for approximately 60% of our international revenues.

8:07 In addition, Iridex acquired Topcon's Pascal laser product line, adding it to our Micropulse and Texel Retina scanning laser platform. And Topcon purchased 10% of Iridex's common shares. The total deal netted $19.5 million in new funds to Iridex. We saw immediate results from the collaboration, including a 10% revenue contribution to our top line from sales of Pascal products we acquired under the agreement and began selling in the last three weeks of the quarter following its closing. In April, we began notifying our affected international distributors of our transition to Topcon's distribution network, and we are actively working in these regions to transition and onboard new distributors while minimizing any potential mid-year disruption to sales volumes.

9:01 We have high confidence in the potential for this collaboration and look forward to updating you on our progress and results as we work through the integration. Next, I'd like to take a few minutes to talk about where we are focused now and highlight some of the investments for growth that we're making in our sales organization. Late last year, we assessed the timing was right to expand our sales team and invest in further clinical and market development efforts to accelerate sales, particularly in glaucoma products. In the first quarter, we executed the following. First, we split and expanded the U.S. sales team, going from 12 hybrid territories selling both glaucoma and retina products to 12 dedicated glaucoma territories and 6 dedicated retina territories.

9:51 We shifted some internal staffing and hired to fill the remaining new positions. Training and activities are essentially complete and we expect the new members will soon be ramping up their contributions. We began increasing our investments in clinical evidence and closer key opinion leader relationships that can improve confidence and adoption of our non-incisional transcleral laser therapy products. And finally, we budgeted for the anticipated return of in-person trade meetings and local clinical events that will require greater investment, but we expect to pay off downstream. Of note, we are exhibiting live at the Hawaiian Eye and Retina Meeting, our first significant non-virtual event since February of 2020.

10:41 This is the first meeting in which we showcase the Pascal Laser and our new 810 Laser. Both the reception and attendance at the meeting have been good. Later this year, we plan to attend an expanding schedule of live domestic and international events, including the American Society of Cataract and Refractive Surgery meeting in July in Las Vegas, the American Society of Retina Specialists in October in San Antonio, the European Society of Cataract and Refractive Surgery in Amsterdam during October, and the American Academy of Ophthalmology meeting in New Orleans in November. As we enter the second quarter and look towards the remainder of the year, our company is emerging from the pandemic in a strong position.

11:29 We're optimistic we can overcome the obvious challenges from continued pockets of COVID resurgence in international regions, the shift in parts of our international distribution network, and how quickly our sales and marketing investments can generate results. We have made significant progress throughout the past year despite extraordinary circumstances. Our focus continues to be on capitalizing on our opportunities for growth and increasing the long-term shareholder value of Airdex. With that, I'd like to turn the call over to Fuad.

12:06 Thank you, Dave, and good afternoon, everyone. I will now go over our financial performance for the first quarter of fiscal 21, starting with revenue. Total revenue for the first quarter of fiscal 21 was $12 million, up 33% from $9 million in the first quarter of last year and down only slightly sequentially. Revenue from Grokoma Product Family in the first quarter of fiscal 21 was $3.3 million, up 15% compared to the first quarter of fiscal 20. We sold 13,600 G6 pearls in the quarter, up 4% from the same period last year and essentially flat sequentially. We saw particularly strong year-over-year growth outside of the U.S. despite COVID-related headwinds worldwide.

12:53 We sold 64 Cyclo-G6 systems in the first quarter of fiscal 21 compared to 38 in the prior period and 57 in the fourth quarter of fiscal 20. We believe the increase in system sales reflects resumption of customer appetite for investments in capital equipment that can lead to future G6 probe utilization. Moreover, one indicator of the underlying strength of our glaucoma business is demonstrated by the relatively small sequential quarterly decline in glaucoma revenue compared to historical fourth quarter to first quarter decline. Our retina product revenue improved significantly in the first quarter of fiscal 21, posting a 61% increase compared to the same period last year.

13:40 Although our results for the first quarter of fiscal 21 include revenue from our acquisition of the Pascal product line from Topcon, even adjusting for Pascal revenue, year-over-year growth was approximately 35%. Other revenue, which includes royalties, services, and other legacy products, were approximately $2 million in the first quarter of fiscal 21 and flat compared to the prior year period. Gross margin in the first quarter of fiscal 21 declined 210 basis points to 41.3% compared to the first quarter of fiscal 20. Gross margin decline is primarily attributable to a greater portion of the revenue coming from our retina wholesale business, including Pascal product line, which runs a low margin. However, overall average selling prices across our product lines remain relatively flat year-over-year and sequentially.

14:40 Operating expenses for the first quarter fiscal 21 were $6.8 million compared to $5.6 million in the same period of prior year, a 22% increase. The increase was due primarily to additional expenses from the acquisition of the Pascal business and certain non-recurring TopCon transaction and integration expenses. Net loss in the first quarter of fiscal 21 was $2 million, or a net loss of $0.14 per share up from $1.7 million, or a net loss of $0.12 per share from last year. Cash usage in the first quarter was $1.1 million, including approximately $500,000 of non-recurring TopCon transaction payments.

15:28 We ended the first quarter of fiscal 21 with cash and cash equivalents of $28 million up from $11.6 million from the end of fiscal 20. The increase in cash is a result of proceeds from the TopCon transaction offset by the cash burn in the period. Turning to our outlook for the remainder of the year. As the world slowly emerges from the pandemic, we're becoming increasingly confident in our ability to forecast. We also feel it is important for us to share our longer-term view of the business with our shareholders and investors, even in these somewhat uncertain times. Therefore, we will resume our prior practice of providing plurial guidance.

16:13 With that said, our guidance for Fiscal 21 is as follows. We expect total revenue for Fiscal 21 to be between $48 million to $51 million. G6 probe sails are expected to range from 56,000 to 59,000 and cyclo G6 glaucoma laser system sails are expected to range from 250 units to 275 units. With that, Dave and I would like to turn the call over to the operator for questions. Operator? Thank you. As a reminder, to ask a question, you will need to press star 1 on your telephone.

16:58 To withdraw your question, press the pound key. Please stand by while we compile the Q&A roster. Our first question comes from John Block with Stiefel. Your line is now open.

17:10 Hey guys, this is Tom Steffen on for John. Thanks for the questions. I'll maybe start off on guidance. G6 expectations for the year were just a bit light of where we were, particularly in probes. So Dave, maybe you can just talk to that a bit and how we should think about maybe the progression of the year. I mean, it sounds like international is very strong and U.S. maybe came back in the second half of 1Q, so any color there would be helpful. Sure, Tom.

17:43 So, yeah, international rebounded. It had been slight declines in prior quarters, and it rebounded. And, you know, this is a quarter-over-quarter kind of thing, right? It's not a steady march. There's some volatility involved. So they were down for a couple quarters sequentially and then just had a strong comeback. And it was almost... The flip side, in the U.S., it had been quite strong in third and fourth quarter and just was slightly behind now. And we really do think that a lot of that was, as I mentioned in the comments, the relative strength of the first quarter last year and the first half of the first quarter this year still had pretty significant restrictions in a lot of geographies around the U.S. as COVID cases were peaking.

18:40 We just think it's part of the bouncing around from quarter to quarter. In terms of the longer term, it's difficult to forecast, as I think you've seen in others, where the transitions occur, where the surge returns. We're very comfortable that we're driving adoption. We're encouraged to see new systems placements that indicate new customers want to adopt the technology. The trick is in the rate at which that comes along. We're still a bit conservative, possibly, on how that develops through the course of the year, whether there's some impact mid-year as we transition some of the distributors internationally, and how that unfolds in the course of this year.

19:36 2021 is clearly going to have some transition elements to it. overlaying the underlying fundamental strength. So we're very encouraged in general and just looking out quarter over quarter to try to be practical in the actual events that occur.

19:59 Great, all helpful caller. I'm actually going to stick with guidance and then maybe go back to G6 a bit. But, you know, if you do some implied math with the revenue guidance, we're getting to a roughly $15 million G6 number for the year and then nearly $35 million for retina and other. of 8.7 mil, give or take, annualized, already gets you to that $35 million number we're calculating, but you haven't really experienced the full contribution from Pascal or the new lasers falling out in that one huge number. So, you know, kind of a long-winded intro there, but, you know, are we thinking about this the right way? And, you know, can you just maybe talk to the pushes and pulls for Retina and other...

20:54 Yeah, so Retina also experienced some surge internationally, similar to the experience of glaucoma probes. So there's that component overlaid in the first quarter. And then there's also the potential transition as existing distributors potentially sell their remaining inventory. Topcon comes up to speed acquiring inventory, adopting the sales and distribution in those areas. And we're certainly allowing for some flat areas as that transition occurs. We haven't seen the full impact of Pascal sales in a quarter yet, but we did see bring some inventory into the quarter that we were able to sell. So the impact in the quarter was relatively strong for the short portion of the quarter that we were booking revenue from the Pascal product line.

21:59 Got it. That makes sense. Maybe last one for me. Just on going back to G6 and utilization there, you know, the change in the G6 selling approach has been in place for, I think, close to two years now. And the second-gen probe has also been out there for, I think, well over a year now. So, you know, Dave, maybe you can talk to this, you know, just around are you seeing the mix of utilization increase sort of downstream in the mild to moderate glaucoma population? Or, you know, has it still largely stayed consistent in the more advanced patient pool?

22:44 We're clearly strongest in the more advanced patient pool segment. Our efforts are focused on making clinicians comfortable with more moderate-stage patients and making the decision to treat pre-incisional. And I think that segment is growing, but I think it takes time and people's experience, and then they want to have a chance to see the durability. So, you know, track. Patience for a couple of quarters and see how long we're really getting the results. We're confident the results are there, but we're also cognizant that they need to have that experience as well. So it's an unfolding story. I think that shift is still largely a big opportunity for us, and that's one of the things we're focused on.

23:36 Part of the reason why we've expanded our direct sales force in the U.S., to really deliver that message more strongly and have engaged a broader set of key opinion leaders to help support that message so that it's coming from the clinical community rather than coming from Iridex. I think those are all things we'll see pay off during 2021.

24:04 That's great. I think that's it for me. Thanks, guys. Okay, next question. The next question comes from Scott Henry with Roth Capital. Your line is now open.

24:17 Thank you, and good afternoon. Certainly busy times for you these days. A couple questions. Retina, in excluding Pascal, has been very strong in Q4 and in Q1 of 2021. How do you think about Retina, kind of ex-Pascal, in Q2 versus Q1, sequentially?

24:47 Well, we're... Very encouraged that Retina has rebounded for Iridex. We made some specific investments in the area, improved the product line. We refocused some sales and marketing efforts there. And I think as we're seeing the world try to emerge from COVID pandemic, were experiencing a return to order volumes internationally and domestically, and were winning a good share of that business. So we're quite encouraged by that, and we are cognizant that it's possible there's a bit of a rebound effect going on in the short term, since there were a lot of deferred orders, and so we're optimistic that that and many others.

25:37 So, that's the challenge in forecasting. We feel like we have better visibility and we have a stronger position in the marketplace, but there's still going to be ebbs and flows through the rest of the year.

26:05 Yeah, I'm just trying to look at it from a full year perspective and get a sense of How this trajectory should play through. Would you expect second quarter revenues to be higher than the first quarter? You are getting a benefit from a full TopCon quarter in there as well. Just trying to get a sense. And along that line, would you expect systems sold to tick up and 2Q from first quarter? I guess with the understanding that I would expect the second half to be stronger than the first half. Thank you for joining us.

27:03 that we see in the mix of business. And short of advising on that, at this point in the quarter, we're giving full year guidance. But like I said to one of the earlier questions, I do think our strength in selling segments has increased and our product offerings are more competitive. And so we're comfortable with the guidance that we've given.

27:34 Okay, fair enough. And then shifting over to the expense items, I believe operating expenses were about $6.8 million in first quarter. What portion of the quarter was TopCon in there? And how many one-time expenses would we kind of think about deal-related in that first quarter?

28:03 Yeah, so let me answer that. So in Q1, we had approximately $600,000 of one-time expenses, transaction-related, integration-related, just of non-recurring. I mean, so those will not, you know, come up again in the subsequent quarters. However, I think you also recognize that Q1 only had one month of the TopCon or the Pascal business acquisition expenses. So those will continue at full clip quarterly rate. So I think if you're looking at OpEx quarter over quarter, you should expect a slight increase over Q1.

28:49 So one-time expenses, a trading off, but they're really, you know, you take over the full burden of the Pascal business going forward. And so they were stacked. And then finally, we are, you know, going to see a pickup in sales and marketing expense. Dave already pointed out in his prepared remarks that they're already seeing resumption of activities in the trade shows and and our sales folks will end up traveling again. So there's going to be uptick in sales and marketing expense. So you should see a slight uptick from that plus the full quarter of the Pascal business. So expect OPEX to be slightly above, not meaningful, but slightly above where we were in Q1.

29:43 Okay, thank you. That's helpful. And then I don't think the 10Q is out yet, and there are a lot of moving levers. Where would you expect shares to be in real time right now?

29:56 Approximately 15.5 is the quarter end number, and we expect that to kind of change very minimally going forward.

30:08 Okay, great. And then, David, I think you said that the pricing on the glaucoma side was pricing stable, just kind of backing it out right now until we get to 10Q, but I just wanted to get a sense of how pricing was relative to Q4. Okay.

30:30 actually it's both on the system side as well as on the probe side on the glaucoma. It's been fairly stable throughout 20 and into 21. We haven't seen any degradation either internationally or U.S. in terms of ASPs and there hasn't been any pricing pressure that we've experienced.

30:58 Okay, great. Thank you for taking the questions. Thanks, Scott. Thank you. I'm not seeing any further questions at this time. I would now like to turn the call back over to David Bruce for closing remarks.

31:13 Thank you, Operator. And thank you all for joining the call. Appreciate your support and look forward to reporting on our progress in the future. Thank you.

Follow IRIDEX Corporation into a list and get an email when it puts out news.

Latest news releases

Companies on this call

Speakers

Tom Steffen

Analyst, Stiefel Financial Partners

Hunter Cobby

Investor Relations

Dave Bruce

Chief Executive Officer

Scott Henry

Analyst, Roth Capital

Vlad Amon

Interim Chief Financial Officer

More from IRIDEX Corporation